[PDF][PDF] Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate …
EJ Small, PF Schellhammer, CS Higano, CH Redfern… - J clin Oncol, 2006 - academia.edu
EJ Small, PF Schellhammer, CS Higano, CH Redfern, JJ Nemunaitis, FH Valone, SS Verjee…
J clin Oncol, 2006•academia.eduPlacebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in
Patients with Metastatic, Asymptomatic Page 1 Placebo-Controlled Phase III Trial of Immunologic
Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone
Refractory Prostate Cancer Eric J. Small, Paul F. Schellhammer, Celestia S. Higano, Charles H.
Redfern, John J. Nemunaitis, Frank H. Valone, Suleman S. Verjee, Lori A. Jones, and Robert M.
Hershberg A B S T R A C T Purpose Sipuleucel-T (APC8015) is an investigational …
Patients with Metastatic, Asymptomatic Page 1 Placebo-Controlled Phase III Trial of Immunologic
Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone
Refractory Prostate Cancer Eric J. Small, Paul F. Schellhammer, Celestia S. Higano, Charles H.
Redfern, John J. Nemunaitis, Frank H. Valone, Suleman S. Verjee, Lori A. Jones, and Robert M.
Hershberg A B S T R A C T Purpose Sipuleucel-T (APC8015) is an investigational …
Purpose
Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against prostatic acid phosphatase. A phase III study was undertaken to evaluate the safety and efficacy of sipuleucel-T in a placebo-controlled study.
academia.edu